Poseida Therapeutics (PSTX) Stock Price, News & Analysis

Company Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $9.50 to $9.50
• 50-Day Range: $9.33 to $9.60
• 52-Week Range: $2.32 to $9.67
• Volume: N/A
• Average Volume: 1.12 million shs
• Market Capitalization: $928.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Hold

Poseida Therapeutics Stock Analysis - MarketRank™

Poseida Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 909th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Poseida Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Poseida Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Poseida Therapeutics has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PSTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Poseida Therapeutics does not currently pay a dividend.

Dividend Growth

Poseida Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Short Interest

There is no current short interest data available for PSTX.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.90% of the stock of Poseida Therapeutics is held by insiders.

Percentage Held by Institutions

46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PSTX Stock Analysis - Frequently Asked Questions

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.42) by $0.63. The company earned $71.75 million during the quarter, compared to the consensus estimate of $15 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 72.26% and a negative net margin of 40.28%.

When did Poseida Therapeutics IPO?

Poseida Therapeutics (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Poseida Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 9/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PSTX
• CIK: 1661460
• Web: www.poseida.com
• Phone: 858-779-3100
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Poseida Therapeutics: $9.50
• High Price Target: $10.00
• Low Price Target: $9.00
• Potential Upside/Downside: 0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$123.43 million
• Net Margins: -40.28%
• Pretax Margin: -40.25%
• Return on Equity: -72.26%
• Return on Assets: -21.53%

Debt

• Debt-to-Equity Ratio: 0.68
• Current Ratio: 3.20
• Quick Ratio: 3.20

Sales & Book Value

• Annual Sales: $150.86 million
• Price / Sales: 6.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 8.80

Miscellaneous

• Outstanding Shares: 97,774,000
• Free Float: 94,939,000
• Market Cap: $928.85 million
• Optionable: Optionable
• Beta: 1.63